Hyphens Pharma International’s subsidiary has extended its partnership with Medac Gesellschaft für klinische Spezialpräparate (medac) to include Thailand and Cambodia for the commercialization of an autoinjector pen.
This builds on the existing agreement signed in March 2025 which granted Hyphens Pharma exclusive rights to register and commercialise the Metoject® subcutaneous autoinjector pen in Singapore, Malaysia, the Philippines, and Vietnam.
The inclusion of Thailand and Cambodia is part of Hyphens Pharma’s strengthening of its footprint across Southeast Asia, the release reads.
The autoinjector pen is an injection treatment for patients with rheumatoid arthritis and plaque psoriasis, offering a therapeutic option with better bioavailability and reduced gastrointestinal side effects compared to oral methotrexate.
The group says this is not expected to have a material impact on its net tangible assets or earnings per share for the current financial year.
Shares in Hyphens Pharma closed 1 cent lower or 2.778% down at 35 cents on Oct 16.
